GT1 on Ontario lithium fast track
Export Development Canada could provide up to C$100 million to finance Green Technology Metals’ Seymour lithium project.
Stockhead
Wildcat top stock for contrarian lithium bet
Barry FitzGerald says if the consensus has gold and uranium stocks leading the way in 2025, lithium could surprise.
Road to 2025: RCE
Sarah Hughan explores Recce Pharmaceuticals and a series of successes advancing a new class of synthetic anti-infectives.
Morgans’ ASX health picks for 2025
Morgans healthcare and life sciences experts Iain Wilkie and Scott Power give Stockhead readers their top picks for 2025.
More Stories
BlinkLab gains FDA support for trial
BlinkLab has received a positive outcome from a pre-submission meeting with the FDA on a regulatory pathway for its BlinkLab Dx 1 platform as an autism diagnosis aid.
Road to 2025: PRX
Sarah Hughan delves into Prodigy Gold and its advancement towards shovel-ready in its proven, yet underexplored end of the Tanami.
Neurizon gains EU orphan status for motor neurone drug
European Medicines Agency grants orphan drug designation for Neurizon’s lead drug candidate NUZ-001 to treat Amyotrophic Lateral Sclerosis.
Fed triggers Wall Street (and ASX) sell-off
The ASX plunged nearly 2pc earlier, as a brutal Wall Street sell-off followed the Fed’s cautious outlook, signalling just two rate cuts for 2025.
Adisyn wraps up due diligence on 2DG
Adisyn’s acquisition of 2DG could help capture opportunities in the hot and emerging semiconductor market.
Guy on Rocks: MNB
Guy Le Page looks into Minbos Resources and a phosphate opportunity to build a breadbasket in a nation which imports all of its fertiliser.
Stem-cell treatment gets breakthrough FDA approval
After years of trying, Mesoblast has won US FDA approval for its stem-cell therapies to treat the fatal graft-versus-host disease.
Volkswagen buys stake in PMT
Stockhead TV’s Sarah Hughan delves into a Volkswagen deal with Patriot Battery Metals and its North American lithium.
Brinsden’s Patriot inks major lithium deal
Volkswagen battery subsidiary PowerCo will pay C$69 million for a 9.9% stake in Canadian lithium hopeful Patriot Battery Metals.
Positive interim results for Trytamine IBS trial
Tryptamine reports positive interim analysis for its phase 2a clinical study of oral psilocybin formula TRP-8802 in patients with IBS.
Original URL: https://www.adelaidenow.com.au/business/stockhead/page/7